Belantamab mafodotin vs Idecabtagene vicleucel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Belantamab mafodotin

Marketed by GlaxoSmithKline

Approved in Multiple Myelomaantibody-drug conjugate (anti-BCMA, MMAF payload)
Partial signal

NCT04246047 · Phase 3 · active, not recruiting

Patients were randomized (243 vs 251) against an active comparator and the primary endpoint of progression-free survival, assessed by an independent review committee, was met with a large separation (hazard ratio 0.41, p<0.00001). The study was open-label with no masking of participants or investigators, which keeps it below the highest grade.

Next expected readout: February 2027 · NCT05055063 (registry estimate)

Reported efficacy

Progression-free Survival (PFS) (Up to approximately 41 months): Progression-free Survival (PFS) (Up to approximately 41 months): Belantamab Mafodotin + Bortezomib (Bor) + Dexamethasone (Dex) 36.6 Months vs Daratumumab + Bor + Dex 13.4 Months (95% CI 11.1 to 17.5) (met)

Result source: NCT04246047

Idecabtagene vicleucel

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomacell therapy (autologous CAR-T)
Reliable signal

NCT03651128 · Phase 3 · completed

Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).

Next expected readout: May 2027 · NCT05393804 (registry estimate)

Reported efficacy

Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)

Result source: NCT03651128

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBelantamab mafodotinIdecabtagene vicleucel
PFS, median36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
8.9bn 137NCT03361748
OS, median24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
28.3bn 137NCT03361748
ORR41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
74.5%bn 137NCT03361748
VGPR or better25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
—Not posted · NCT03651128
MRD negativity—Trial running · NCT06679101—Not posted · NCT03651128

PFS, median

Belantamab mafodotin
36.6 vs 13.4vs Daratumumabn 243NCT04246047
13 other results
  • 11.2 vs 7 n 218 · Phase 3 · primary NCT04162210
  • 3.2 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 3.9 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 2.2 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 2.8 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 3.6 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 5.7 2.5 mg/kg Q3W · n 29 · Phase 2 · secondary NCT05064358
  • 2.8 2.5 mg/kg Q6W · n 30 · Phase 2 · secondary NCT05064358
  • 2.5 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · secondary NCT03848845
  • 2.1 1.9 mg/kg Q3W · n 30 · Phase 2 · secondary NCT05064358
  • 2.7 1.9 mg/kg Q6W · n 34 · Phase 2 · secondary NCT05064358
  • 2.8 1.9 mg/kg Q6W · n 11 · Phase 2 · secondary NCT05064358
Idecabtagene vicleucel
8.9bn 137NCT03361748

OS, median

Belantamab mafodotin
24 vs 22.9vs Pomalidomide Plus Dexamethasonen 218NCT04162210
7 other results
  • 14 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 15.3 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 24.5 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 20.9 2.5 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 13.5 2.5 mg/kg Q6W · n 25 · Phase 2 · secondary NCT05064358
  • 15 1.9 mg/kg Q3W · n 23 · Phase 2 · secondary NCT05064358
  • 14.5 1.9 mg/kg Q6W · n 21 · Phase 2 · secondary NCT05064358
Idecabtagene vicleucel
28.3bn 137NCT03361748

ORR

Belantamab mafodotin
41% vs 36%vs Pomalidomide Plus Dexamethasonen 218NCT04162210
35 other results
  • 34% 3.4 mg/kg · n 99 · Phase 2 · primary NCT03525678
  • 31% 2.5 mg/kg · n 97 · Phase 2 · primary NCT03525678
  • 48% 3.4 mg/kg · n 25 · Phase 2 · primary NCT03525678
  • 30% 3.4 mg/kg · n 66 · Phase 2 · primary NCT03525678
  • 30% 2.5 mg/kg · n 64 · Phase 2 · primary NCT03525678
  • 50% 3.4 mg/kg SPLIT · n 12 · Phase 1/2 · primary NCT03544281
  • 69% 3.4 mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 69% 2.5mg/kg SINGLE · n 16 · Phase 1/2 · primary NCT03544281
  • 92% 2.5 mg/kg Step-Down STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 2.5 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 62% 2.5 mg/kg SPLIT · n 13 · Phase 1/2 · primary NCT03544281
  • 78% 2.5 mg/kg SINGLE · n 18 · Phase 1/2 · primary NCT03544281
  • 43% 2.5 mg/kg + 200 mg · n 28 · Phase 1/2 · primary NCT03848845
  • 58% 1.9mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 50% 1.9 mg/kg STRETCH · n 12 · Phase 1/2 · primary NCT03544281
  • 83% 1.9 mg/kg SINGLE · n 12 · Phase 1/2 · primary NCT03544281
  • 75% 1.9mg/kg SINGLE · n 4 · Phase 1/2 · primary NCT03544281
  • 32% 3.4 mg/kg · n 99 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 97 · Phase 2 · secondary NCT03525678
  • 52% 3.4 mg/kg · n 25 · Phase 2 · secondary NCT03525678
  • 26% 3.4 mg/kg · n 66 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg · n 64 · Phase 2 · secondary NCT03525678
  • 33% 2.5 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 28% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 25% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 43% 3.4 mg/kg + 200 mg · n 7 · Phase 1/2 · secondary NCT03848845
  • 67% 2.5 mg/kg + 200 mg · n 6 · Phase 1/2 · secondary NCT03848845
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
  • 25% 3.4 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg · n 4 · Phase 1 · secondary NCT03828292
  • 100% 2.5 mg/kg + Bor/Dex · n 3 · Phase 1 · secondary NCT03828292
  • 50% 2.5 mg/kg + Pom/Dex · n 4 · Phase 1 · secondary NCT03828292
  • 16.7% n 6 · Phase 1 · secondary NCT04177823
Idecabtagene vicleucel
74.5%bn 137NCT03361748

VGPR or better

Belantamab mafodotin
25%b2.5 mg/kg Q3W · n 40NCT05064358
4 other results
  • 8% 2.5 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q3W · n 40 · Phase 2 · secondary NCT05064358
  • 15% 1.9 mg/kg Q6W · n 40 · Phase 2 · secondary NCT05064358
  • 18% 1.9 mg/kg Q6W · n 17 · Phase 2 · secondary NCT05064358
Idecabtagene vicleucel
—Not posted · NCT03651128

MRD negativity

Belantamab mafodotin
—Trial running · NCT06679101
Idecabtagene vicleucel
—Not posted · NCT03651128
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Belantamab mafodotin: 9 of 10 rows · Idecabtagene vicleucel: 9 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBelantamab mafodotinIdecabtagene vicleucel
Duration of Response
time to event · months
No placebo or comparator arm
12.6 months3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 9 more doses
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
6.2 months3.4 mg/kg
NCT03525678 · Phase 2
15.9 months3.4 mg/kg
NCT03525678 · Phase 2
5.3 months3.4 mg/kg
NCT03525678 · Phase 2
9 months3.4 mg/kg
NCT03525678 · Phase 2
12.4 months2.5 mg/kg
NCT03525678 · Phase 2
6.9 months2.5 mg/kg
NCT03525678 · Phase 2
12.5 months2.5 mg/kg
NCT03525678 · Phase 2
11 months2.5 mg/kg
NCT03525678 · Phase 2
11.04 monthsb,c,d
NCT03361748 · Phase 2
ORR
responder rate · % of participants
No placebo or comparator arm
34% (n=99)3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 9 more doses
30% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
32% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
26% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
48% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
52% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
31% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
30% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
33% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
74.5% (n=137)b,c,d
NCT03361748 · Phase 2
Overall Survival
time to event · months
No placebo or comparator arm
14 months3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 2 more doses
24.5 months3.4 mg/kg
NCT03525678 · Phase 2
15.3 months2.5 mg/kg
NCT03525678 · Phase 2
28.25 monthsb,c,d
NCT03361748 · Phase 2
PFS
time to event · months
No placebo or comparator arm
3.2 months3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 5 more doses
3.9 months3.4 mg/kg
NCT03525678 · Phase 2
3.6 months3.4 mg/kg
NCT03525678 · Phase 2
5.7 months3.4 mg/kg
NCT03525678 · Phase 2
2.2 months2.5 mg/kg
NCT03525678 · Phase 2
2.8 months2.5 mg/kg
NCT03525678 · Phase 2
8.9 monthsb,c,d
NCT03361748 · Phase 2
Time to Progression
time to event · months
No placebo or comparator arm
3.9 months3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 5 more doses
4.9 months3.4 mg/kg
NCT03525678 · Phase 2
3.6 months3.4 mg/kg
NCT03525678 · Phase 2
5.7 months3.4 mg/kg
NCT03525678 · Phase 2
2.2 months2.5 mg/kg
NCT03525678 · Phase 2
2.9 months2.5 mg/kg
NCT03525678 · Phase 2
10.38 monthsb,c,d
NCT03361748 · Phase 2
Time to Response
time to event · months
No placebo or comparator arm
1.5 months3.4 mg/kga,b,c,d
NCT03525678 · Phase 2
show 9 more doses
1.5 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
1.4 months3.4 mg/kg
NCT03525678 · Phase 2
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
0.9 months3.4 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.4 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1.5 months2.5 mg/kg
NCT03525678 · Phase 2
1 monthsb,c,d
NCT03361748 · Phase 2
Dropout rate
n/a: no completion milestonee
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
42.2%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
n/a: no completion milestone2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
75%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
80%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
82.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
77.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
58.8%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
50%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
77.8%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
87.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
69.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
75%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
42.9%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
32.1%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
25%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
33.3%
NCT04177823 · Phase 1 · registry result, not featured evidence
16.7%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
73.7%f
NCT03361748 · Phase 2
show 1 more result
5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—e
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
—
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—3.4 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg
NCT03525678 · Phase 2
—2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
—1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
—3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
—3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
—
NCT04177823 · Phase 1 · registry result, not featured evidence
—4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
—f
NCT03361748 · Phase 2
show 1 more result
—
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
50%e
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
46.5%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
53.5%3.4 mg/kg
NCT03525678 · Phase 2
62.5%3.4 mg/kg
NCT03525678 · Phase 2
100%3.4 mg/kg
NCT03525678 · Phase 2
45.3%2.5 mg/kg
NCT03525678 · Phase 2
100%2.5 mg/kg
NCT03525678 · Phase 2
43.6%2.5 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
53.8%2.5 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
42.5%1.9 mg/kg Q3W
NCT05064358 · Phase 2 · registry result, not featured evidence
40%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence
23.5%1.9 mg/kg Q6W
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
56.3%3.4 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
72.2%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
53.8%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
62.5%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
46.2%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%2.5 mg/kg Step-Down STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%2.5mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5mg/kg SPLIT
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
66.7%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
25%1.9 mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
50%1.9 mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
0%1.9mg/kg SINGLE
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
33.3%1.9mg/kg STRETCH
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
71.4%3.4 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
66.7%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
17.9%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
0%3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
50%2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
0%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
25%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50%2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
0%2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
16.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
50%4.60 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
33.3%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
48.6%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%3.40 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%2.50 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
50%1.92 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.96 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.48 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.24 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
25%0.12 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.06 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
0%0.03 mg/kg
NCT02064387 · Phase 1 · registry result, not featured evidence
78.8%f
NCT03361748 · Phase 2
show 1 more result
22.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
e
thrombocytopenia 69%
vision blurred 66.1%
dry eye 50.8%
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 56 more results
vision blurred 48.4%
dry eye 37.8%
foreign body sensation in eyes 36.9%
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
3.4 mg/kg
keratopathy 74.7%
thrombocytopenia 44.4%
anaemia 36.4%
NCT03525678 · Phase 2
3.4 mg/kg
keratopathy 95.8%
fatigue 50%
anaemia 33.3%
NCT03525678 · Phase 2
3.4 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg
keratopathy 70.5%
anaemia 26.3%
nausea 25.3%
NCT03525678 · Phase 2
2.5 mg/kg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03525678 · Phase 2
2.5 mg/kg Q3W
vision blurred 41%
dry eye 38.5%
eye irritation 28.2%
NCT05064358 · Phase 2 · registry result, not featured evidence
2.5 mg/kg Q6W
vision blurred 46.2%
thrombocytopenia 33.3%
anaemia 30.8%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q3W
thrombocytopenia 42.5%
anaemia 30%
dry eye 30%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
anaemia 37.5%
dry eye 30%
eye irritation 27.5%
NCT05064358 · Phase 2 · registry result, not featured evidence
1.9 mg/kg Q6W
vision blurred 52.9%
dry eye 47.1%
eye irritation 29.4%
NCT05064358 · Phase 2 · registry result, not featured evidence · combination
3.4 mg/kg SINGLE
keratopathy 93.8%
thrombocytopenia 56.3%
neuropathy peripheral 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
keratopathy 83.3%
thrombocytopenia 75%
fatigue 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
keratopathy 83.3%
vision blurred 66.7%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
keratopathy 76.9%
thrombocytopenia 69.2%
vision blurred 38.5%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg STRETCH
keratopathy 100%
platelet count decreased 58.3%
gamma-glutamyltransferase increased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
keratopathy 100%
platelet count decreased 58.3%
diarrhoea 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
keratopathy 68.8%
fatigue 43.8%
thrombocytopenia 43.8%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
keratopathy 92.3%
vision blurred 53.8%
diarrhoea 46.2%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg Step-Down STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
2.5mg/kg SPLIT
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
keratopathy 91.7%
platelet count decreased 75%
constipation 66.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
keratopathy 75%
diarrhoea 50%
platelet count decreased 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
diarrhoea 75%
keratopathy 75%
abdominal pain 50%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
keratopathy 75%
diarrhoea 41.7%
insomnia 41.7%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9 mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg SINGLE
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
1.9mg/kg STRETCH
abdominal discomfort 0%
abdominal distension 0%
abdominal pain 0%
NCT03544281 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg + 200 mg
keratopathy 85.7%
pyrexia 57.1%
anaemia 42.9%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 100%
anaemia 66.7%
blepharitis 50%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
keratopathy 71.4%
pyrexia 35.7%
vision blurred 35.7%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
2.5 mg/kg + 200 mg
alanine aminotransferase increased 0%
anaemia 0%
arthralgia 0%
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
3.4 mg/kg
diarrhoea 50%
enterocolitis 50%
headache 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg
platelet count decreased 100%
alanine aminotransferase increased 50%
aspartate aminotransferase increased 50%
NCT03828292 · Phase 1 · registry result, not featured evidence
2.5 mg/kg + Bor/Dex
thrombocytopenia 100%
diarrhoea 66.7%
insomnia 66.7%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
constipation 50%
neutrophil count decreased 50%
oedema peripheral 50%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Bor/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
2.5 mg/kg + Pom/Dex
abdominal pain upper 0%
abnormal faeces 0%
alanine aminotransferase increased 0%
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
blood lactate dehydrogenase increased 66.7%
hyponatraemia 66.7%
lymphocyte count decreased 66.7%
NCT04177823 · Phase 1 · registry result, not featured evidence
4.60 mg/kg
thrombocytopenia 83.3%
aspartate aminotransferase increased 66.7%
fatigue 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 100%
aspartate aminotransferase increased 66.7%
chills 66.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 51.4%
cough 40%
aspartate aminotransferase increased 37.1%
NCT02064387 · Phase 1 · registry result, not featured evidence
3.40 mg/kg
vision blurred 33.3%
anaemia 16.7%
blood creatine phosphokinase increased 16.7%
NCT02064387 · Phase 1 · registry result, not featured evidence
2.50 mg/kg
anaemia 37.5%
fatigue 37.5%
nausea 37.5%
NCT02064387 · Phase 1 · registry result, not featured evidence
1.92 mg/kg
nausea 75%
vision blurred 75%
chills 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.96 mg/kg
anaemia 66.7%
fatigue 66.7%
chills 33.3%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.48 mg/kg
arthralgia 50%
back pain 25%
decreased appetite 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.24 mg/kg
fatigue 50%
nausea 50%
anaemia 25%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.12 mg/kg
cough 50%
hypercalcaemia 50%
nausea 50%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.06 mg/kg
anaemia 100%
diarrhoea 100%
hyperuricaemia 100%
NCT02064387 · Phase 1 · registry result, not featured evidence
0.03 mg/kg
fatigue 100%
neutropenia 100%
osteonecrosis of jaw 100%
NCT02064387 · Phase 1 · registry result, not featured evidence
f
neutropenia 94.9%
cytokine release syndrome 80.3%
anaemia 75.9%
NCT03361748 · Phase 2
show 1 more result
lymphocyte count decreased 85%
neutrophil count decreased 77.5%
white blood cell decreased 72.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. ePopulation comparability has not been reviewed for 55 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Belantamab mafodotin

PFS 36.6 vs 13.4 Daratumumab months
time to event · months
NCT04246047 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
11.2 vs 7 Pomalidomide Plus Dexamethasone months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Overall Survival 24 vs 22.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
ORR 41% (n=218) vs 36% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Clinical Benefit 47% (n=218) vs 47% (n=107) Pomalidomide Plus Dexamethasone
responder rate · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Duration of Response 25.3 vs 9.9 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Response 2.1 vs 1.53 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
Time to Progression 11.3 vs 8.6 Pomalidomide Plus Dexamethasone months
time to event · months
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3
MRD Negativity 10.1% (n=218) vs 0.9% (n=107) Pomalidomide Plus Dexamethasone
event count · % of participants
NCT04162210 · Phase 3 · Multiple Myeloma · phase 3 · converted to % from 22 Participants as posted
Clinical Benefit 38% (n=99)3.4 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT03525678 · Phase 2
show 14 more results
60% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
35% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
40% (n=99)3.4 mg/kg
NCT03525678 · Phase 2
56% (n=25)3.4 mg/kg
NCT03525678 · Phase 2
38% (n=66)3.4 mg/kg
NCT03525678 · Phase 2
75% (n=4)3.4 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
35% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
36% (n=97)2.5 mg/kg
NCT03525678 · Phase 2
34% (n=64)2.5 mg/kg
NCT03525678 · Phase 2
43% (n=28)2.5 mg/kg + 200 mg
NCT03848845 · Phase 1/2 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg
NCT03828292 · Phase 1 · registry result, not featured evidence
100% (n=3)2.5 mg/kg + Bor/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
50% (n=4)2.5 mg/kg + Pom/Dex
NCT03828292 · Phase 1 · registry result, not featured evidence · combination
EORTC QLQ-C30 Global Health Status -4.1 score @ 7wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
show 2 more results
1.5 score @ 7wk3.4 mg/kg
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
-0.7 score @ 7wk2.5 mg/kg
GHS/QoL,Week 07,n=48,47,17
NCT03525678 · Phase 2
EORTC QLQ-C30 Global Health Status 6 score @ 13wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
show 2 more results
1 score @ 13wk3.4 mg/kg
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
-3.2 score @ 13wk2.5 mg/kg
GHS/QoL,Week 13,n=29,29,16
NCT03525678 · Phase 2
EORTC QLQ-C30 Global Health Status 3.7 score @ 19wk3.4 mg/kg
absolute change · score
No placebo or comparator arm
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2
show 2 more results
0 score @ 19wk3.4 mg/kg
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2
-2.2 score @ 19wk2.5 mg/kg
GHS/QoL,Week 19,n=19,27,10
NCT03525678 · Phase 2

+ 305 further endpoints in the CSV export.

Idecabtagene vicleucel

Complete 34.3% (n=137)
responder rate · % of participants
No placebo or comparator arm
NCT03361748 · Phase 2
VGPR or Better With MRD Negativity 40.9% (n=137)
responder rate · % of participants
No placebo or comparator arm
10^(-5) Sensitivity
NCT03361748 · Phase 2
EORTC QLQ-C30 Physical Functioning -0.4 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
2.1 score @ 4.33wk
NCT03361748 · Phase 2
9.8 score @ 13wk
NCT03361748 · Phase 2
13.9 score @ 26wk
NCT03361748 · Phase 2
13.1 score @ 39wk
NCT03361748 · Phase 2
13.3 score @ 52wk
NCT03361748 · Phase 2
12.8 score @ 78wk
NCT03361748 · Phase 2
3.8 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-C30 Global Health Status -4.7 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
4.3 score @ 4.33wk
NCT03361748 · Phase 2
8.8 score @ 13wk
NCT03361748 · Phase 2
12.5 score @ 26wk
NCT03361748 · Phase 2
15.7 score @ 39wk
NCT03361748 · Phase 2
14.1 score @ 52wk
NCT03361748 · Phase 2
10.6 score @ 78wk
NCT03361748 · Phase 2
7.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Disease Symptoms -0.8 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
-10.2 score @ 4.33wk
NCT03361748 · Phase 2
-10.8 score @ 13wk
NCT03361748 · Phase 2
-12.6 score @ 26wk
NCT03361748 · Phase 2
-14.4 score @ 39wk
NCT03361748 · Phase 2
-15.7 score @ 52wk
NCT03361748 · Phase 2
-12 score @ 78wk
NCT03361748 · Phase 2
-13.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Side Effects 2.5 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
0 score @ 4.33wk
NCT03361748 · Phase 2
-2.6 score @ 13wk
NCT03361748 · Phase 2
-4.7 score @ 26wk
NCT03361748 · Phase 2
-6.5 score @ 39wk
NCT03361748 · Phase 2
-4 score @ 52wk
NCT03361748 · Phase 2
-3.4 score @ 78wk
NCT03361748 · Phase 2
-3.2 score @ 104wk
NCT03361748 · Phase 2
EQ-5D-5L Index 0.0314 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
0.0528 score @ 4.33wk
NCT03361748 · Phase 2
0.0998 score @ 13wk
NCT03361748 · Phase 2
0.0974 score @ 26wk
NCT03361748 · Phase 2
0.1067 score @ 39wk
NCT03361748 · Phase 2
0.1097 score @ 52wk
NCT03361748 · Phase 2
0.1101 score @ 78wk
NCT03361748 · Phase 2
0.0383 score @ 104wk
NCT03361748 · Phase 2
CR/sCR 65.8% (n=38) @ 26wk
responder rate · % of participants
No placebo or comparator arm
Acheived CR/sCR by 6 Months post Infusion
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 25 Participants as posted
Cumulative Incidence of Disease Progression 2.6% (n=38) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Response Upgrade 89.5% (n=38) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted
Non Relapse Mortality 0% (n=38) @ 52wk
event count · % of participants
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
PFS12 97.4% (n=38) @ 52wk
absolute value · percentage points
No placebo or comparator arm
NCT05032820 · Phase 2 · registry result, not featured evidence · combination

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Belantamab mafodotin's landscape · Idecabtagene vicleucel's landscape